The Hamburg-based biotech and research company Evotec is raising fresh money through a capital increase, bringing the Abu Dhabi sovereign wealth fund on board as a new major shareholder. In the capital increase without subscription rights, almost 11.48 million shares will be issued, raising 250 million euros, Evotec announced in the early hours of Tuesday morning.
Within the framework of the private placement, the state fund (Mubadala Investment Company) will invest 200 million euros, the company announced. This corresponds to a stake of about 5.6 percent. The remainder will be secured by Evotec's shareholder Novo Holdings A/S, which thus continues to hold a share of approximately 11 percent in Evotec. The new shares will be issued at a subscription price of 21.7802 euros per share. This is 3.4 percent below the last closing price. Evotec intends to use the money to further expand its business.
Notice: No person, organization and/or company shall disseminate or broadcast the above article on Xinhua Silk Road website without prior permission by Xinhua Silk Road.
A single purchase
